Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

NCT02429466 is registered in ClinicalTrials.gov with Nasser Hanna as lead sponsor.

NCT NCT02429466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02429466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Lead sponsor
Nasser Hanna
Phase
Phase 1
Overall status
Completed
Start date
April 27, 2015
Completion date
February 13, 2019
Enrollment
14 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

germ cell tumor, testicular cancer, testis cancer